Figures & data
Table 1 Studies of pretreatment T790M mutation
Table 2 Studies of posttreatment-acquired T790M mutation
Table 3 Quality assessment of studies included in the pretreatment T790M mutation group
Table 4 Quality assessment of studies included in the posttreatment-acquired T790M mutation group
Table 5 Summary of heterogeneity and publication bias in all studies included in the meta-analysis
Figure 2 Forest plots of pooled HRs and 95% CIs for PFStotal (A) and OStotal (B) according to pretreatment de novo T790M mutation status.
Abbreviations: CI, confidence interval; HR, hazard ratio; OStotal, overall survival for all lines of epidermal growth factor-tyrosine kinase inhibitor treatment; PFStotal, progression-free survival for all lines of epidermal growth factor-tyrosine kinase inhibitor treatment.
![Figure 2 Forest plots of pooled HRs and 95% CIs for PFStotal (A) and OStotal (B) according to pretreatment de novo T790M mutation status.](/cms/asset/c8987841-05b6-4e1a-8e09-4df6c4f8204f/dott_a_12195484_f0002_c.jpg)
Figure 3 Forest plots of pooled HRs for all PFSfirst-line (A) and RRs for ORRtotal (B) according to pretreatment de novo T790M mutation status.
Abbreviations: CI, confidence interval; HRs, hazard ratios; PFSfirst-line, progression-free survival for first-line of epidermal growth factor-tyrosine kinase inhibitor treatment; ORRtotal, objective response rate for all lines of epidermal growth factor-tyrosine kinase inhibitor treatment; RR, relative ratio.
![Figure 3 Forest plots of pooled HRs for all PFSfirst-line (A) and RRs for ORRtotal (B) according to pretreatment de novo T790M mutation status.](/cms/asset/5e4398a0-c1d6-4aa6-9378-67d118844645/dott_a_12195484_f0003_c.jpg)
Figure 4 Forest plots of HRs and 95% CIs for PFS (A) and PPS (B) according to acquired T790M mutation status.
![Figure 4 Forest plots of HRs and 95% CIs for PFS (A) and PPS (B) according to acquired T790M mutation status.](/cms/asset/8e9ee19a-3cb9-4614-97b1-d0e6961051b8/dott_a_12195484_f0004_c.jpg)
![Figure 4 Forest plots of HRs and 95% CIs for PFS (A) and PPS (B) according to acquired T790M mutation status.](/cms/asset/43b395cb-a770-4f89-b309-2b5757e6194b/dott_a_12195484_f0004a_c.jpg)
Figure 5 Forest plots of HRs for OS (A) and RR for ORR (B) according to acquired T790M mutation status.
Abbreviations: CI, confidence interval; ctDNA, circulating tumor DNA; HRs, hazard ratios; ORR, objective response rate; OS, overall survival; RR, relative ratio.
![Figure 5 Forest plots of HRs for OS (A) and RR for ORR (B) according to acquired T790M mutation status.](/cms/asset/12fb2266-391e-40d1-af72-ff8bcc2d089a/dott_a_12195484_f0005_c.jpg)